Turning Point Therapeutics Inc.
Industry
- Biotechnology
- Pharmaceuticals
Other Names/Subsidiaries
- Bristol Myers Squibb Company
- TP Therapeutics, Inc
Latest on Turning Point Therapeutics Inc.
The knockback of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd. 's patritumab deruxtecan (DXd) in June, and the late-stage lung cancer misfire of AstraZeneca PLC and Daiichi Sankyo’s datopotamab
The knockback of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd. ’s patritumab deruxtecan (DXd) this week, and the late-stage lung cancer misfire of AstraZeneca PLC and Daiichi Sankyo’s datopotama
A second approval for Bristol Myers Squibb Company ’s cancer drug Augtyro (repotrectinib) has provided further validation of BMS’s $4.1bn acquisition of Turning Point Therapeutics Inc. in 2022. [Si
Venture capital investment in biopharmaceutical companies ticked higher in the first quarter of 2024. In the second quarter, money is flowing into VC investors and funds focused specifically on the li